KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Assets Average (2016 - 2025)

Historic Assets Average for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $814.3 million.

  • Pacific Biosciences Of California's Assets Average fell 4497.03% to $814.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $814.3 million, marking a year-over-year decrease of 4497.03%. This contributed to the annual value of $1.5 billion for FY2024, which is 1442.14% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Assets Average is $814.3 million, which was down 4497.03% from $843.1 million recorded in Q2 2025.
  • Pacific Biosciences Of California's Assets Average's 5-year high stood at $2.0 billion during Q4 2021, with a 5-year trough of $814.3 million in Q3 2025.
  • Over the past 5 years, Pacific Biosciences Of California's median Assets Average value was $1.7 billion (recorded in 2024), while the average stood at $1.6 billion.
  • In the last 5 years, Pacific Biosciences Of California's Assets Average surged by 53816.21% in 2021 and then crashed by 4696.32% in 2025.
  • Pacific Biosciences Of California's Assets Average (Quarter) stood at $2.0 billion in 2021, then fell by 11.26% to $1.8 billion in 2022, then increased by 1.63% to $1.8 billion in 2023, then fell by 25.62% to $1.4 billion in 2024, then tumbled by 39.91% to $814.3 million in 2025.
  • Its Assets Average was $814.3 million in Q3 2025, compared to $843.1 million in Q2 2025 and $1.1 billion in Q1 2025.